NEW ON THE MARKET
Overactive bladder: vibegron (OBGEMSA) and what's new with mirabegron (BETMIGA)
New indication: dupilumab (DUPIXENT) also for COPD
THERAPY FROM A CRITICAL VIEWPOINT
Interventional procedures for chronic back pain: benefit proven?
a-t READERS QUESTIONS AND COMMENTS
Low-dose naltrexone for fibromyalgia: what is the evidence?
IN BRIEF
Benzene in external acne treatment products containing benzoyl peroxide: batches recalled in the US free article
SIDE EFFECTS
Heavy menstrual bleeding very common during anticoagulation
Homicidal thoughts and serotonin syndrome with atomoxetine
Non-steroidal anti-inflammatory drugs plus cholinesterase inhibitors: risk of peptic ulcer increased
e a-t ON THE INTERNET
New indication: dupilumab (DUPIXENT) also for COPD (long version)
Addendum: misleading advertising for ORTOTON (methocarbamol)